Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q2 CY2026, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter's revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts' estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts' consensus estimates.
Is now the time to buy BSX? Find out in our full research report (it's free).
Revenue: $5.44 billion vs analyst estimates of $5.36 billion (7.5% year-on-year growth, 1.5% beat)
Adjusted EPS: $0.86 vs analyst estimates of $0.83 (3.8% beat)
Revenue Guidance for Q3 CY2026 is $5.27 billion at the midpoint, below analyst estimates of $5.39 billion
Management lowered its full-year Adjusted EPS guidance to $3.30 at the midpoint, a 2.2% decrease
Operating Margin: 21.6%, up from 16.2% in the same quarter last year
Market Capitalization: $68.43 billion
Boston Scientific's second quarter was shaped by healthy growth in its Interventional Cardiology, Endoscopy, and Neuromodulation businesses, which counterbalanced notable slowdowns in Electrophysiology and the WATCHMAN left atrial appendage closure device. CEO Michael Mahoney acknowledged the unexpected pace of U.S. market changes for WATCHMAN and competitive pressures in Electrophysiology, both of which led to a more cautious outlook. Management described the environment as "dynamic" and outlined how clinical evidence and referral patterns directly affected WATCHMAN volumes. The company also cited integration progress with recent acquisitions as a positive contributor to segment performance.
Looking ahead, Boston Scientific's revised guidance reflects sustained market headwinds in Electrophysiology and WATCHMAN for the remainder of the year and likely into 2027. Mahoney stated that, "we expect our revenue and EPS growth profile to improve meaningfully in 2028, supported by key catalysts across Boston Scientific." The company is focusing on new product launches, cost discipline through a restructuring program, and targeted investments in growth areas. However, management cautioned that ongoing changes in referral patterns, competitive dynamics, and the timing of new product rollouts could limit earnings growth in the near term.
Management attributed the quarter's momentum to strength in core businesses and integration of recent acquisitions, while acknowledging that rapid shifts in clinical adoption and competitive activity caused deviations from previous expectations.
Interventional Cardiology Outperformance: The segment delivered strong growth, driven by robust demand for complex coronary interventions, drug-coated balloons, and advanced imaging capabilities. New data from the FRACTURE trial supported future launches, with management citing the upcoming SEISMIQ 4CE Coronary IVL Catheter as a future growth lever.
WATCHMAN Slowdown: WATCHMAN procedure growth slowed sharply due to new clinical evidence influencing stroke prevention referrals, as well as operational bottlenecks from the rapid adoption of concomitant procedures (when WATCHMAN is implanted during another cardiac surgery). U.S. stand-alone procedures declined, while international WATCHMAN growth remained comparatively stronger.
Electrophysiology Competitive Pressures: Electrophysiology grew internationally but faced notable U.S. share losses. The company cited faster-than-expected adoption of pulsed-field ablation (PFA) devices, with Boston Scientific's technology holding leadership but now facing more intense competition, especially in the U.S.
Neuromodulation Integration: The Neuromodulation business saw double-digit growth, supported by the full-quarter contribution of the Nalu acquisition and expansion of the brain and pain therapy portfolio. Management highlighted progress with product integrations and new programming technologies.
Cost Discipline and Restructuring: A company-wide restructuring program was announced, targeting $500 million in run-rate savings by 2029. Management expects savings to come first from SG&A and later from supply chain, enabling reinvestment in growth platforms and margin improvement from 2028 onward.
Boston Scientific's near-term outlook is shaped by persistent pressures in key U.S. franchises and delayed benefit from new product launches and restructuring efforts.
WATCHMAN and EP Headwinds: Management expects ongoing challenges in both WATCHMAN and Electrophysiology through next year. The WATCHMAN slowdown is driven by evolving clinical guidelines and referral patterns, while U.S. EP faces intensified competition and changing technology adoption rates. These factors are expected to weigh on both revenue and margins in the near term.
Restructuring and Cost Actions: The newly announced restructuring program aims to deliver substantial expense savings, with over half targeted by the end of 2027. While these efforts will impact SG&A first, meaningful operating margin expansion is not expected until 2028 as the company continues investing in strategic growth areas.
Pipeline and New Market Expansion: Management pointed to seven major product launches planned for 2028 and beyond, including new ablation technologies, IVL devices, and expanded cardiovascular offerings. The closing of the Penumbra acquisition and entry into new adjacencies are expected to support a return to higher growth rates starting in 2028.
In the coming quarters, the StockStory team will be monitoring (1) the pace of recovery and mitigation strategies for U.S. WATCHMAN and Electrophysiology, (2) progress in integrating the Penumbra acquisition and its cardiovascular portfolio, and (3) execution of restructuring initiatives aimed at cost savings. The timing and success of key product launches and regulatory milestones will also be critical markers for improved performance.
Boston Scientific currently trades at $46.12, in line with $46.06 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it's free for active Edge members).
WHILE YOU'RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.